Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions  by Hoye, Angela et al.
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OBJECTIVES The aim of this study was to assess sirolimus-eluting stent (SES) implantation for the
treatment of chronic total coronary occlusions (CTO).
BACKGROUND Long-term results after percutaneous coronary intervention (PCI) in the treatment of CTOs
is hindered by a significant rate of restenosis and reocclusion. In the treatment of relatively
simple nonocclusive lesions, SESs have shown dramatically reduced restenosis rates compared
with bare metal stents (BMS), but whether these results are more widely applicable is
unknown.
METHODS From April 2002, all patients at our institution were treated with SES as the device of choice
during PCI. During the first six months, 563 patients were treated solely with SES, with
treatment of a de novo CTO in 56 (9.9%). This CTO cohort was compared with a similar
group of patients (n  28) treated in the preceding six-month period with BMS.
RESULTS At one year, the cumulative survival-free of major adverse cardiac events was 96.4% in the
SES group versus 82.8% in the BMS group, p  0.05. At six-month follow-up, 33 (59%)
patients in the SES group underwent angiography with a binary restenosis rate (50%
diameter stenosis) of 9.1% and in-stent late loss of 0.13  0.46 mm. One patient (3.0%) at
follow-up was found to have reoccluded the target vessel.
CONCLUSIONS The use of SESs in the treatment of chronic total coronary occlusions is associated with a
reduction in the rate of major adverse cardiac events and restenosis compared with
BMS. (J Am Coll Cardiol 2004;43:1954–8) © 2004 by the American College of
Cardiology FoundationM
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phronic total occlusions (CTO) are common, and found in
pproximately one-third of patients with significant coro-
ary disease who undergo angiography (1,2). Percutaneous
ntervention (PCI) of CTOs accounts for 10% to 15% of all
ngioplasties; however, after successful recanalization, there
s an increased rate of subsequent restenosis and reocclusion
ompared with nonocclusive stenoses (3,4). Although sev-
ral randomized trials demonstrated the efficacy of stent
mplantation over balloon-only angioplasty, even with stents
here remains a significant rate of both restenosis (32% to
5%) and reocclusion (8% to 12%) (5–9).
In the treatment of relatively simple lesions, sirolimus-
luting stents (SES) markedly reduce the restenosis rate,
ith continued benefit documented up to two years
ollow-up (10,11). Whether these results can be extrapo-
ated to more complex lesions such as CTOs has yet to be
etermined. We sought to evaluate the effectiveness of the
ES in a consecutive series of patients with at least one de
ovo CTO compared with a similar series treated with bare
etal stents (BMS).
From the Department of Interventional Cardiology, Erasmus MC, Rotterdam, the
etherlands.
Manuscript received October 29, 2003; revised manuscript received January 15,i004, accepted January 19, 2004.ETHODS
atient population. Commencing in April 2002, all PCI
t our institution was done solely with SESs, irrespective of
linical presentation or lesion morphology; these patients
omprise the Rapamycin-Eluting Stent Evaluated at Rot-
erdam Cardiology Hospital registry (RESEARCH) regis-
ry (further details of the methodology are described else-
here) (12,13). Those deemed at an increased risk of
estenosis (including the CTO population) were considered
or six-month angiographic follow-up. Sirolimus-eluting
tents were available in lengths between 8 mm and 33 mm,
nd diameters 2.25 mm to 3.0 mm. In the first six months,
63 patients were treated, including 56 (9.9%) with success-
ul revascularization of at least one CTO. These patients
ake up the present study cohort; all received six months
ual antiplatelet therapy with clopidogrel in addition to
spirin. As predetermined by the RESEARCH protocol,
his study cohort of patients were compared with all those
reated for a CTO in the preceding six months with BMS,
dentified from the departments’ dedicated database. Both
roups were treated by the same operators utilizing standard
echniques, the only difference being the type of stent. The
rotocol was approved by the local ethics committee and is
n accordance with the principles of Good Clinical Practice
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June 2, 2004:1954–8 Sirolimus-Eluting Stents in Chronic Occlusionsor Trials of Medicinal Products in the European Commu-
ity and the Declaration of Helsinki. All patients signed a
ritten informed consent
TO definition. Chronic occlusion was defined as an
cclusion on angiography with no antegrade filling of the
istal vessel other than via collaterals. All patients included
ad a native vessel occlusion estimated to be at least one
onth’s duration (9) based on either a history of sudden
hest pain, a previous acute myocardial infarction in the
ame target vessel territory, or the time between the diag-
osis made on coronary angiography and PCI.
ength of occlusion. The length of occlusion was mea-
ured by quantitative coronary angiography either utilizing
ntegrade filling via collaterals, or assessment of the retro-
rade collateral filling. This was achieved by catheterizing
oth the left and right coronary arteries, and making a
imultaneous injection to delineate the distance between the
ite of occlusion and the most proximal part of the vessel
lled retrogradely.
ollow-up. Patients were followed up prospectively and
valuated for survival-free of major adverse cardiac events
MACE) using questionnaires and telephone enquiries;
ACE was predefined as: 1) death; 2) nonfatal myocardial
nfarction; or 3) repeat target vessel revascularization
TVR). The diagnosis of acute myocardial infarction re-
uired an elevation of creatine kinase to twice the upper
imit of normal, together with a rise in creatine kinase-MB
raction. Target vessel revascularization was defined as
ither surgical or percutaneous reintervention driven by
ignificant (50%) luminal narrowing within the treated
essel, and was undertaken in the presence of either anginal
ymptoms or objective evidence of ischemia.
ngiographic analysis. Quantitative analysis in those SES
atients with follow-up angiography was undertaken in
hree coronary segments: in-stent (encompassing the entire
ength of stented segment), and the 5-mm proximal and
istal edge segments either side of the in-stent segment.
he target lesion comprised the in-stent plus the proximal
nd distal edge segments. Binary restenosis was defined as
50% diameter stenosis within the target lesion. Late
umen loss was calculated from the difference in minimal
umen diameter between postprocedure and follow-up.
tatistical analysis. Discrete variables are presented as
ercentages and compared with Fisher exact test. Continu-
Abbreviations and Acronyms
BMS  bare metal stent
CTO  chronic total occlusion
MACE  major adverse cardiac events
PCI  percutaneous coronary intervention
RESEARCH  Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital registry
SES  sirolimus-eluting stent
TVR  target vessel revascularizationus variables are expressed as mean  SD and compared Sith Student t test. Survival-free of adverse events was
alculated according to the Kaplan-Meier method. The
og-rank test was used to compare MACE-free survival
etween the two groups. All tests were two-tailed, and a p
alue of 0.05 was considered statistically significant.
ESULTS
he baseline patient and lesion characteristics of the two
roups are presented in Tables 1 and 2. One patient in the
MS group underwent successful recanalization and stent
mplantation in two CTOs, thereby making a total of 29
esions in this group. Mean length of occlusion could be
etermined in 45 (80.4%) of the SES group and 17 (58.6%)
f the BMS group. There was no significant difference
etween the groups with respect to the postprocedural
uantitative angiography; however, the mean diameter of
tent utilized was greater in the BMS cohort.
There were no in-hospital MACE. Clinical follow-up
ata was obtained in 100% of both groups. There were no
eaths in either group; one non–Q-wave acute myocardial
nfarction occurred related to subacute stent thrombosis 11
ays after SES implantation. This was successfully recana-
ized percutaneously; intravascular ultrasound suggested un-
erexpansion of the SES (2.5  33 mm), and the patient
as treated with abciximab and balloon dilation of the
reviously implanted stent. At one year, the cumulative
urvival-free of MACE was 96.4% in the SES group
ompared with 82.8% in the BMS group, p  0.05 (Fig. 1).
ne patient in each group had a reocclusion (1.8% SES
roup vs. 3.6% BMS group, p  NS).
At six months, 33 (58.9%) patients in the SES group
nderwent follow-up angiography (none in the BMS group)
Table 3). The binary restenosis rate was 9.1%: one occlu-
ion, one stenosis at the ostium of a side branch after
able 1. Baseline Patient Demographics
Bare Stents
n  28
SES
n  56
p
Value
ean age (yrs) 59.8  11.1 60.2  10.0 0.9
ale gender (%) 85.7 71.4 0.2
urrent smoker (%) 35.7 26.8 0.5
iabetes mellitus (%) 7.1 14.3 0.4
ypertension (%) 39.3 39.3 1.0
ypercholesterolemia (%) 57.1 55.4 1.0
revious myocardial
infarction (%)
46.4 55.4 0.6
revious PCI (%) 21.4 12.5 0.3
revious CABG (%) 0 0 –
lycoprotein IIb/IIIa
inhibitor usage (%)
25.0 21.4 1.0
resence of multivessel
disease (%)
60.7 46.3 0.3
CI in at least one additional
(nonoccluded) major
epicardial vessel during the
index procedure (%)
28.6 42.6 0.2
ABG coronary artery bypass grafting; PCI percutaneous coronary intervention;
ES  sirolimus-eluting stents.
T
(
r
s
g
o
f
a
w
t
c
D
P
r
s
(
s
t
7
w
e
e
r
p
a
m
0
m
t
f
s
S
i
e
a
e
s
T
A
N
P
F
i
1956 Hoye et al. JACC Vol. 43, No. 11, 2004
Sirolimus-Eluting Stents in Chronic Occlusions June 2, 2004:1954–8-stenting, and the third at the distal outflow of the SES
this is the same patient with the subacute thrombosis, and
estenosis occurred at the site of balloon dilation during the
econd procedure). The patient with occlusion had under-
one bifurcation T-stenting after successful recanalization
f a heavily calcified left anterior descending artery. At
ollow-up, the artery had reoccluded, and there was new
kinesis of the left ventricular anterior wall. This patient
ith occlusion was managed with medical therapy; the other
wo patients with restenosis underwent percutaneous revas-
ularization.
ISCUSSION
revious studies have demonstrated the importance of
evascularization of CTOs, with improvement in anginal
ymptoms, exercise capacity, and left ventricular function
14–16). In addition, successful recanalization reduces the
ubsequent need for bypass surgery and, importantly, long-
erm evaluation has shown a 10-year survival advantage of
Table 2. Baseline Procedural Characteristics
Target vessel
LAD (%)
LCX (%)
RCA (%)
Mean length of occlusion (mm, range)
Bifurcation stenting (%)
Mean number of stents in the target vessel
Mean nominal diameter of stent in the main
vessel (mm)
Mean length of stent in the main vessel (mm)
Mean total length of overlapping stents in the
main vessel (mm, range)
Postprocedure vessel reference diameter (mm)
QCA data
Minimal lumen diameter (mm)
Diameter stenosis (%)
LAD  left anterior descending artery; LCX  circumflex
coronary artery; SES  sirolimus-eluting stents.
igure 1. Kaplan-Meier curves for survival-free of death, acute myocardial
nfarction, or target vessel revascularization.3.5% after successful PCI compared with 65.1% in those
ith unsuccessful PCI (4,17).
To our knowledge, this is the first report regarding the
fficacy of SES in CTOs, a subset of patients previously
xcluded from other protocols and, importantly, at increased
isk of developing restenosis after conventional stent im-
lantation (3). Of the patients who underwent follow-up
ngiography, both the in-stent and proximal 5-mm seg-
ents analyzed showed an encouraging late loss of 0.13 
.46 mm and 0.10  0.80 mm, respectively. The distal 5
m actually showed an overall benefit, with enlargement of
he vessel (late loss, 0.06  0.54 mm).
In addition to the angiographic data, the clinical
ollow-up is very encouraging. Importantly, there were no
ignificant differences in baseline demographics between the
ES and BMS groups, and all procedures were carried out
n the same center by the same operators. There was an
pisode of subacute thrombosis in the SES group, but there
ppears to be an underlying mechanical cause with under-
xpansion of the stent documented on intravascular ultra-
ound. The restenosis rate for BMS is known to be inversely
are Stents
n  29
SES
n  56 p Value
0.06
27.6 51.8
27.6 25.0
44.8 23.2
7 (2.4–31.8) 11.3 (4.0–32.1) 0.5
17.9 14.3 1.0
1.8 2.0 1.0
.03  0.56 2.75  0.26  0.001
.31  9.34 23.89  9.21 0.7
.8 (18–112) 45.2 (8–117) 0.7
.37  0.50 2.35  0.46 0.9
.18  0.49 2.06  0.48 0.3
10.4 11.6 0.6
QCA  quantitative coronary angiography; RCA  right
able 3. Postprocedural and Six-Month Follow-Up Quantitive
ngiographic Data for the Sirolimus-Eluting Stent (Patient
umber n  33)
Proximal
5 mm In-Stent
Distal
5 mm
ostprocedure
Mean diameter (mm) 2.82  0.66 2.58  0.55 2.10  0.64
Minimal lumen
diameter (mm)
2.43  0.51 2.04  0.45 1.75  0.53
% Diameter stenosis 14.1 12.9 21.8
Six-month follow-up
Mean diameter (mm) 3.02  0.53 2.46  0.81 2.12  0.83
Minimal lumen
diameter (mm)
2.33  0.90 1.91  0.68 1.81  0.75
% Diameter stenosis 20.1 21.9 18.2
Late lumen loss (mm) 0.10  0.80 0.13  0.46 0.06  0.54B
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June 2, 2004:1954–8 Sirolimus-Eluting Stents in Chronic Occlusionselated to the postprocedural minimal lumen diameter and
he number of stents utilized (18). In the current study,
lthough the mean diameter of stent used was significantly
reater in the BMS cohort (related to a maximum available
ES diameter of 3.0 mm) with free utilization of postdila-
ion, the postprocedural minimal lumen diameter was not
ignificantly different between the two groups. The majority
f events related to TVR, with, at one year, a significantly
igher rate of survival free of MACE of 96.4% in the SES
roup versus 82.8% in the BMS group.
Four major randomized trials have demonstrated the
fficacy of stent implantation over balloon-only angioplasty
n the treatment of CTOs, reducing the six-month reste-
osis rate from 68% to 74%, to 32% to 55% (5–8).
ompared with this historical data, our study suggests that
he SES confers a marked further advantage with a signif-
cantly lower binary restenosis rate of 9.1% (p  0.05) (Fig.
). In addition, we had only one patient (3.0%) with vessel
eocclusion, compared with rates of between 8% to 12% in
he same published trials utilizing BMS. A recent study of
he clinical results of 376 patients discharged from hospital
ithout an adverse event after successful intervention of a
TO showed, at one-year follow-up, a MACE rate of
2.2% (19); our results are, therefore, quite remarkable, with
MACE-free survival rate of 96.4%.
tudy limitations. This study evaluated only a small cohort
f patients, and angiographic follow-up was not obtained in
ll, so additional patients with silent reocclusion cannot be
xcluded. However, those who did not undergo repeat
ngiography were all symptomatically well at follow-up. In
ddition, despite the discrepancy in follow-up angiography
ates between the two groups, which might have biased the
esults towards more revascularization in the SES group, the
igure 2. The percentage binary restenosis rate (50% diameter stenosis)
nd reocclusion rate of Rapamycin-Eluting Stent Evaluated at Rotterdam
ardiology Hospital registry (RESEARCH) compared with published
ata from the patients treated with stent implantation in the randomized
rials Stenting in Chronic Coronary Occlusion (SICCO) (5), Gruppo
taliano di Studio sullo Stent nelle Occlusioni Coronariche (GISSOC) (6),
tents in Total Occlusion for Restenosis Prevention (STOP) (7), and the
otal Occlusion Study of Canada (TOSCA) (8). DS  diameter stenosis.
p 0.05 compared with the results of RESEARCH; †p 0.01 compared
ith the results of RESEARCH.ACE rate remained statistically significant with a bene-cial effect in favor of the SES. The study was not
andomized, and used a retrospective comparitive popula-
ion; however, the same operators and interventional tech-
iques were utilized.
onclusions. The use of SESs in the treatment of complex
atients with CTOs is associated with a reduction in the
ate of MACE and restenosis compared with BMS.
eprint requests and correspondence: Dr. Patrick W. Serruys,
epartment of Interventional Cardiology, Thoraxcentre Bd 404,
r Molewaterplein 40, NL-3015 GD Rotterdam, the Nether-
ands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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